Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 381 clinical trials
featured
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Background: Chronic lymphocytic leukemia (CLL) is a cancer of white blood cells. It is also called small lymphocytic lymphoma (SLL). It causes tiredness, night sweats, weight loss, swollen lymph nodes, easy bruising or bleeding, and frequent infections. Researchers want to test if a drug combination is effective and safe for …

TP53
chronic lymphocytic leukemia
cancer
fludarabine
lymphocytosis
  • 47 views
  • 23 Nov, 2020
  • 1 location
Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

A randomised trial for children with acute lymphoblastic leukemia, using the detection of minimal residual disease to define risk groups, aiming to answer the questions: 1. Can

minimal residual disease
residual tumor
remission
lymphoid leukemia
  • 9 views
  • 07 Nov, 2020
  • 1 location
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

months and < 22 years at diagnosis, with residual disease to investigate the possible activity of HD-MTX by giving to all patients the benefit of VEC chemotherapy whilst randomising half of patients

  • 25 views
  • 24 Jan, 2021
  • 62 locations
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the ELN criteria.

  • 10 views
  • 21 Jan, 2021
  • 37 locations
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more …

dactinomycin
combination chemotherapy
doxorubicin
vinorelbine
etoposide
  • 103 views
  • 07 Nov, 2020
  • 9 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 29 Apr, 2021
  • 37 locations
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. …

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Next Generation Sequencing NGS Monitors Minimal Residual Disease MRD in Allo-PBSCT Patients

Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation.

  • 0 views
  • 23 Jan, 2021
  • 1 location
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

transplantation (AHSCT) allows to long-term remission and in some cases complete and definitive eradication of the disease. After chemotherapy or antibodies, the Minimal Residual Disease (MRD

lymphoid leukemia
fludarabine
graft versus host disease
remission
cell transplantation
  • 11 views
  • 07 Nov, 2020
  • 1 location
  • 0 views
  • 26 Jan, 2021
  • 1 location